LAVA Therapeutics (NASDAQ:LVTX) Short Interest Update

LAVA Therapeutics (NASDAQ:LVTX) saw a large increase in short interest in February. As of February 28th, there was short interest totalling 387,300 shares, an increase of 1,443.0% from the February 13th total of 25,100 shares. Based on an average trading volume of 448,100 shares, the short-interest ratio is presently 0.9 days. Approximately 3.0% of the shares of the stock are short sold.

LAVA Therapeutics Price Performance

LAVA Therapeutics stock opened at $1.35 on Thursday. The firm has a 50 day simple moving average of $1.06 and a 200-day simple moving average of $1.41. LAVA Therapeutics has a 1-year low of $0.85 and a 1-year high of $4.21. The stock has a market cap of $35.49 million, a price-to-earnings ratio of -1.31 and a beta of 0.48.

LAVA Therapeutics (NASDAQ:LVTX) last posted its quarterly earnings results on Tuesday, December 10th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.11). Equities analysts expect that LAVA Therapeutics will post -1.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Citizens Jmp cut shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 11th. HC Wainwright reaffirmed a “neutral” rating and set a $1.50 price objective (down previously from $2.00) on shares of LAVA Therapeutics in a research note on Thursday, February 27th. Leerink Partnrs cut shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. Leerink Partners reaffirmed a “market perform” rating and set a $2.00 price objective (down previously from $11.00) on shares of LAVA Therapeutics in a research note on Thursday, December 12th. Finally, JMP Securities reaffirmed a “market perform” rating and set a $6.00 price objective on shares of LAVA Therapeutics in a research note on Wednesday, December 11th. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, LAVA Therapeutics has an average rating of “Hold” and an average price target of $3.17.

Institutional Trading of LAVA Therapeutics

Hedge funds have recently made changes to their positions in the company. Virtu Financial LLC acquired a new position in shares of LAVA Therapeutics in the 3rd quarter worth approximately $32,000. BNP Paribas Financial Markets acquired a new position in shares of LAVA Therapeutics in the 4th quarter worth approximately $40,000. Finally, Sanofi acquired a new position in shares of LAVA Therapeutics in the 4th quarter worth approximately $1,825,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.